Northland Securities restated their buy rating on shares of Invuity, Inc. (NASDAQ:IVTY) in a research report report published on Tuesday. They currently have a $13.00 price target on the medical instruments supplier’s stock.
Several other research firms have also recently commented on IVTY. Zacks Investment Research cut Invuity from a hold rating to a sell rating in a research report on Monday, May 1st. Stifel Nicolaus reiterated a buy rating and set a $10.00 price target (up from $9.00) on shares of Invuity in a research report on Thursday, April 27th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. Invuity has an average rating of Buy and a consensus price target of $15.43.
Invuity (NASDAQ:IVTY) traded up 7.19% during mid-day trading on Tuesday, reaching $7.45. The company’s stock had a trading volume of 341,498 shares. Invuity has a 52 week low of $4.50 and a 52 week high of $14.25. The firm’s market capitalization is $126.46 million. The firm’s 50 day moving average price is $8.27 and its 200 day moving average price is $7.35.
Invuity (NASDAQ:IVTY) last posted its earnings results on Wednesday, April 26th. The medical instruments supplier reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.03. Invuity had a negative net margin of 140.08% and a negative return on equity of 119.36%. The business had revenue of $9.02 million during the quarter, compared to analyst estimates of $8.71 million. On average, analysts anticipate that Invuity will post ($2.24) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Invuity’s (IVTY) “Buy” Rating Reiterated at Northland Securities” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/05/19/invuitys-ivty-buy-rating-reiterated-at-northland-securities.html.
In other news, Director Reza Zadno sold 4,000 shares of the firm’s stock in a transaction on Wednesday, May 3rd. The stock was sold at an average price of $9.16, for a total transaction of $36,640.00. Following the completion of the sale, the director now directly owns 8,800 shares of the company’s stock, valued at approximately $80,608. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Eric W. Roberts acquired 5,000 shares of Invuity stock in a transaction dated Monday, May 15th. The shares were bought at an average cost of $7.88 per share, with a total value of $39,400.00. Following the completion of the purchase, the director now owns 101,529 shares in the company, valued at $800,048.52. The disclosure for this purchase can be found here. 13.84% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the company. Interwest Venture Management Co. bought a new stake in Invuity during the fourth quarter valued at $6,212,000. Venator Capital Management Ltd. bought a new stake in Invuity during the third quarter valued at $3,780,000. Integre Asset Management LLC raised its stake in Invuity by 43.6% in the fourth quarter. Integre Asset Management LLC now owns 26,469 shares of the medical instruments supplier’s stock valued at $152,000 after buying an additional 8,038 shares in the last quarter. Iguana Healthcare Management LLC bought a new stake in Invuity during the third quarter valued at $1,372,000. Finally, Deerfield Management Co. raised its stake in Invuity by 31.8% in the fourth quarter. Deerfield Management Co. now owns 1,690,498 shares of the medical instruments supplier’s stock valued at $9,720,000 after buying an additional 407,900 shares in the last quarter. 66.48% of the stock is owned by institutional investors and hedge funds.
Receive News & Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.